SoCal IP MCLE meeting May 10, 2021

Our weekly SoCal IP Institute meeting on Monday, May 10, 2021 will be a discussion of two Federal Circuit cases: Functional Claim “Raises the Bar for Enablement” In Amgen v. Sanofi and Regeneron (Fed. Cir. 2021) (available - Amgen case) the CAFC provided another anti-functional-limitation decision — this time rendering Amgen’s monoclonal antibody claims invalid.  [...]

SoCal IP Institute :: July 1, 2013 :: The Line Between Patent and Antitrust &Undue Experimentation Under 35 U.S.C. 112

Our weekly SoCal IP Institute meeting on Monday, July 1, 2013 will be a discussion of a recent Supreme Court case regarding the line between patent and antitrust and a Federal Circuit decision on enablement. Brief synopses of the cases appear below. FTC v. Actavis, Inc., Case No. 12-416 (U.S.  June 17, 2013) (available here).  [...]

By |2013-06-28T22:01:26-07:00June 28th, 2013|Antitrust, Patent, Statutory Subject Matter, Enablement|0 Comments
Go to Top